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2000.—We evaluated the levels of 15(S)-hydroxyeicosatetra-
enoic acid [15(S)-HETE] and the expression of 15-lipoxygen-
ase (15-LO) mRNA in induced sputum obtained from 10
control and 15 chronic bronchitis subjects. 15(S)-HETE was
evaluated by reverse phase high-performance liquid chroma-
tography separation followed by specific RIA. 15-LO mRNA
expression was determined by primed in situ labeling. The
levels of both soluble and cell-associated 15(S)-HETE re-
sulted significantly higher in chronic bronchitis than in con-
trol subjects. The percentage of cells expressing 15-LO
mRNA was significantly higher in chronic bronchitis than in
control subjects (P , 0.01). Double staining for specific cell
type markers and 15-LO mRNA showed macrophages and
neutrophils positive for 15-LO, whereas similar staining of
peripheral blood neutrophils did not show evidence for 15-LO
expression, suggesting that expression of 15-LO in neutro-
phils takes place on migration into the airways. Because
15(S)-HETE inversely correlated with the percentage of neu-
trophils in sputum of chronic bronchitis subjects, we studied
the effect of 15(S)-HETE on leukotriene B4 (LTB4) production
in vitro and evaluated the concentration of LTB4 in induced
sputum and the contribution of LTB4 to the chemotactic
activity of induced sputum samples ex vivo. The results
obtained indicate that macrophages and neutrophils present
within the airways of chronic bronchitis subjects express
15-LO mRNA; increased basal levels of 15(S)-HETE may
contribute to modulate, through the inhibition of 5-lipoxy-
genase metabolites production, neutrophil infiltration and
airway inflammation associated with chronic bronchitis.
5-lipoxygenase; 15-lipoxygenase
ARACHIDONIC ACID (AA) metabolites, such as leukotrienes
and prostaglandins (29), play an important role among
the mediators involved in the development of airway
diseases. 15(S)-hydroxyeicosatetraenoic acid [15(S)-
HETE], the product of AA metabolism through the
15-lipoxygenase (15-LO) pathway, represents the main
AA metabolite synthesized by human lung and airways
(9, 12). 15(S)-HETE is a potent mucosecretagogue in
human airways (20) and prolongs the duration of air-
way obstruction during the early response (14), and
15-LO-dependent metabolites can exert several immu-
noregulatory functions that may be relevant in airway
inflammation (33).
Several studies have documented that exogenous or
endogenously generated 15(S)-HETE can be rapidly
metabolized and/or reincorporated into cellular lipids
(1, 4). Airway epithelial cells represent a significant
source of 15(S)-HETE, and ozone exposure increases
15(S)-HETE production by, and reincorporation in, air-
way epithelial cells, leading to reduced synthesis of
PGE2, a cyclooxygenase metabolite of AA that possesses
several anti-inflammatory activities in the airways (2). In
addition, we recently found that reincorporation of 15(S)-
HETE into phospholipids of pulmonary epithelial cells,
as well as the expression of 15-LO, can be modulated
by cytokines such as interleukin-4, suggesting that
15(S)-HETE production is regulated by the pulmonary
microenvironment (25). The biological effect of 15(S)-
HETE reincorporation into membrane phospholipids is
largely unknown, but it seems that such a phenomenon
may exert autocrine functions affecting the response of
inflammatory cells to chemotactic stimuli (4), possibly
through the modification of intracellular signal trans-
duction pathways (16).
Although the role played by 15(S)-HETE has been
extensively studied in asthma, its putative role in
chronic bronchitis still remains largely unknown. In
addition, despite previous in vitro evidence, the poten-
tial role played by 15(S)-HETE reincorporation in cells
isolated from the airways of patients with chronic
airway inflammation is still a matter of debate.
Therefore, the first aim of the present study was to
compare soluble and cell-associated 15(S)-HETE levels
in induced sputum samples obtained from normal and
chronic bronchitis subjects. In addition, to identify
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(among those recovered in induced sputum samples)
the cell(s) possibly contributing to the observed
amounts of released or lipid-incorporated 15(S)-HETE,
we evaluated the phenotype of cells bearing 15-LO
mRNA. Moreover, we evaluated whether the increased
15(S)-HETE levels may influence airway inflamma-
tion. We investigated the ability of 15(S)-HETE to
modulate the production of leukotriene B4 (LTB4), the
most powerful neutrophil chemotactic AA metabolite,
and therefore its ability to affect the migration of
neutrophils into the human airways.
METHODS
Patients. The study was performed on two groups of sub-
jects. The study groups included 10 control and 15 chronic
bronchitis and/or chronic obstructive pulmonary disease
(COPD) subjects. Chronic bronchitis and COPD (median age
68 yr, range 48–78 yr) were defined according to the criteria
of the American Thoracic Society (3). Patients diagnosed as
having COPD had a forced expiratory volume in 1 s (FEV1)
below 70% of that predicted and displayed a 10% or smaller
increase in their FEV1 after an inhaled dose of 200 mg of
albuterol. Patients were excluded if they had a bronchial
infection during the month preceding the study; no subject
had received corticosteroids in any form during the 2 mo
before the study. All chronic bronchitis patients who had
routine chest X-rays and computed tomographic scans that
showed obvious emphysema were excluded. Control subjects
(median age 31 yr, range 25–43 yr) never suffered from
asthma or chronic bronchitis, and they had not experienced
any bronchial or respiratory tract infections during the
month preceding the study. Control subjects were lifelong
nonsmokers, and their pulmonary function was within the
normal range. None of the control and chronic bronchitis
subjects received aspirin during the 7 days before their eval-
uations.
The study was approved by the appropriate ethics commit-
tee, and patients gave written informed consent for partici-
pation.
Induced sputum production and sample processing. Each
subject was submitted to spirometry before the beginning of
the procedure. Induced sputum production and processing
were carried out according to Fahy et al. (8) with slight
modifications (35). Briefly, patients in a fasting condition
were exposed, early in the morning, for 20 min to an aerosol
of 3% hypertonic saline solution. The volume of the induced
sputum, or saliva, was determined, and an equal volume of a
dithiothreitol solution (0.1% in saline solution, vol/vol; Sigma
Chemical, St Louis, MO) was added. Samples were then
gently mixed with a vortex and placed in a water bath at
37°C for 15 min to ensure a complete homogenization. Sam-
ples were periodically removed from the water bath for fur-
ther brief, gentle vortex mixing. The homogenized sputum
and saliva were centrifuged at 800 g for 10 min at room
temperature (RT) to separate the supernatants from the cell
pellet. The supernatants were then aspirated and frozen at
280°C under argon atmosphere into siliconized glass centri-
fuge tubes for subsequent 15(S)-HETE analysis.
The cell pellet was resuspended in saline solution and
filtered through a 70-mm nylon mesh. The eluate was centri-
fuged at 200 g for 5 min at RT, and the cell pellet was finally
resuspended in PBS to a final concentration of 106 cells/ml.
Aliquots (10 ml) were used to assess cell viability by trypan
blue exclusion, whereas differential cell counting was ob-
tained from cytocentrifuged slides (Cytospin 2; Shandon In-
struments, Runcorn, UK) stained with Diff Quick (Merz-
Dade, Dudingen, Switzerland). The slides were read blindly
by two independent investigators who counted at least 400
cells per slide. The number of the squamous cells was sub-
tracted from the total cell counts, and the differential cell
counts were expressed as corrected percentage. A separate
aliquot was centrifuged at 400 g for 10 min at 4°C, and the
cellular pellet was resuspended in 1 ml of PBS and 1 ml of
methanol and stored at 280°C under argon atmosphere into
siliconized glass centrifuge tubes until analysis of cell-asso-
ciated 15(S)-HETE.
Analysis of 15(S)-HETE in supernatants. The superna-
tants from induced sputum samples were acidified with 50 ml
of formic acid. Extraction was carried out on octadecylsilyl
(ODS) cartridges (Supelclean LC-18; Supelco, Bellafonte, PA)
that were activated with 10 ml of ethanol and 10 ml of water.
Supernatants were loaded onto cartridges, washed with 10
ml of water and 5 ml petroleum benzine, and eluted with 4 ml
of ethyl acetate. The ethyl acetate fractions were collected,
evaporated to dryness under a steady flow of nitrogen gas,
and resuspended in 400 ml of acetonitrile:water (20:80, vol/
vol). Reverse phase high-performance liquid chromatography
(RP-HPLC) separation of 15(S)-HETE was carried out with
the use of a Beckman System Gold Liquid Chromatograph
(Beckman Analytical, Palo Alto, CA) equipped with an Ultra-
sphere ODS column (4.6 3 250 mm, 5 mm, Beckman Analyt-
ical). The column was eluted at a flow rate of 1 ml/min using
a linear gradient from 20% solvent B (acetonitrile/acetic acid,
100/0.1, vol/vol) to 100% B over 18 min, with solvent A
represented by water/acetic acid (100/0.1, vol/vol). Retention
time of 15(S)-HETE standard was 21 6 0.6 min, and it was
checked daily with the use of radiolabeled 15(S)-HETE (182
Ci/mmol; NEN Products, Boston, MA). The fractions that
corresponded to the retention time of 15(S)-HETE standard
were collected, pooled, dried under vacuum, reconstituted
with RIA buffer, and then assayed for 15(S)-HETE with a
specific RIA kit (Advanced Magnetic, Framingham, MA) per-
formed according to the manufacturer’s protocol. Cross-reac-
tivity with different eicosanoids, according to the manufac-
turer, was 5-HETE 0.1%; 12-HETE, 0.5%; 5,15-di-HETE and
8,15-di-HETE, 1%; we tested the cross-reactivity for 15(R)-
HETE that resulted ,5%. The lower limit of detection for the
assay was 8.2 pg/tube. All measurements were made in
duplicate, and the results were expressed in nanograms per
corrected cell counts (106 cells/ml).
Analysis of cell-associated 15(S)-HETE. The sputum cells’
suspensions were extracted with 2 vol of 2-propanol contain-
ing 1.2% (vol/vol) acetic acid and chloroform (1:1, vol/vol)
according to Conrad et al. (6). The resulting mixture was
vortexed and centrifuged at 2,500 g for 15 min at RT. The
upper and the intermediate phases were removed, whereas
the lipids containing lower phases were dried under nitrogen
and resuspended in 400 ml of methanol. An aliquot was
treated with 100 ml of NaOH 2N and incubated at 60°C for 30
min under argon atmosphere. The solution was added with
100 ml of acetic acid 2N, and the final volume was adjusted to
800 ml with water. After centrifugation at 2,500 g for 10 min
at RT, samples were analyzed for 15(S)-HETE by RP-HPLC
separation followed by RIA as described above.
Purification of neutrophils from peripheral blood. Periph-
eral blood polymorphonuclear leukocytes were prepared from
normal and chronic bronchitis subjects with the use of dex-
trane sedimentation and centrifugation over Ficoll cushions,
as previously described (26).
Primed in situ labeling of 15-LO mRNA in induced sputum
cells. To identify the cells expressing 15-LO, we performed
primed in situ labeling (PRINS) for 15-LO mRNA, according
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to Koch et al. (11) with minor modifications, as previously
described (25).
At least four fields per slide were evaluated under light
microscopy (3400 final magnification), and a minimum of
400 cells were counted. Results were expressed as the per-
centage of 15-LO mRNA-positive cells over the total.
To identify the phenotype of cells expressing 15-LO
mRNA, PRINS was performed in induced sputum samples
obtained from 10 control and 10 chronic bronchitis subjects
after immunohistochemical characterization by using the
immunoalkaline phosphatase-antialkaline phosphatase
(APAAP) method according to Cordell et al. (7). The following
monoclonal antibodies (MAb) were used: Dako macrophage
(anti-CD68 EBM II; Dakopatts, Glostrup, Denmark; recog-
nizing mononuclear phagocytes; dilution 1:100), Dako neu-
trophil elastase (anti-human neutrophil elastase cell line
NP57, recognizing neutrophils; dilution 1:150), Dako primed
T cells (anti-UCHL1, recognizing antigen-primed T cells;
dilution 1:50), and the MAb anti-eosinophil (EG1) and anti-
eosinophil cationic protein MAb (EG2) (Kabi Pharmacia,
Uppsala, Sweden; dilution 1:5). The slides were read blindly
by two independent investigators who counted at least 400
cells per slide. The evaluation of double immunostaining
resulting from PRINS and immunohistochemistry was done
using light microscopy at a final magnification of 3400.
Positive cells were characterized by a colocalization of the red
and brown staining due to the APAAP and PRINS methods,
respectively. Control slides were included in each staining
session with the use of an irrelevant MAb (anti-smooth mus-
cle; Ortho Pharmaceutical, Raritan, NJ).
Analysis of LTB4 in supernatants. To understand whether,
in chronic bronchitis, the inverse correlation between the
levels of 15(S)-HETE and the percentage of neutrophils could
be related to the levels of the potent neutrophil chemotactic
factor LTB4, we measured LTB4 in induced sputum samples
obtained from chronic bronchitis subjects by RP-HPLC sep-
aration followed by quantitation using a commercial enzyme
immunoassay (RIA), performed according to the manufactur-
er’s directions (Amersham Pharmacia Biotech, Piscataway,
NJ).
The effect of 15(S)-HETE on LTB4 production was studied
in vitro using isolated human neutrophils, challenged either
with the calcium ionophore A-23187 (1 mM, 10 min, 37°C) or
with the formylated tripeptide formyl-methionine-leucine-
phenylalanine (fMLP; 0.1 mM, 10 min, 37°C) on preactivation
with granulocyte/macrophage colony-stimulating factor (GM-
CSF; 1 nM, 30 min, 37°C), as previously described (27, 28). To
test the effect of phospholipid-incorporated 15(S)-HETE onto
LTB4 production, isolated human neutrophils (10
7 cells) were
incubated with 15(S)-HETE (30 mM) for 30 min and washed
before GM-CSF priming and fMLP challenge.
LTB4 and its v-oxidized metabolites were analyzed by
RP-HPLC coupled to diode-array UV detection as previously
described (27, 28).
Neutrophil chemotaxis assay. To lend further support to
the hypothesis that 15(S)-HETE may have a role in inhibit-
ing neutrophil migration within the airways of chronic bron-
chitis subjects, we evaluated the ability of induced sputum
samples from chronic bronchitis patients to induce neutro-
phil chemotaxis and correlated with the levels of 15(S)-
HETE. We therefore selected induced sputum samples ob-
tained from three subjects with 15(S)-HETE concentrations
.8 ng/106 cells [high-15(S)-HETE producers: 50.5 (36–109)
ng/106 cells] and from three subjects with 15(S)-HETE con-
centrations ,8 ng/106 cells [low-15(S)-HETE producers: 2.2
(1.3–6.1) ng/106 cells]. Neutrophils obtained from the periph-
eral blood of healthy donors were resuspended at a concen-
tration of 1 3 106/ml in PBS containing CaCl2 (0.5 mM) and
MgCl2 (1 mM), and the supernatants from induced sputum of
chronic bronchitis patients were tested for their chemotactic
activity on neutrophils. In addition, to evaluate whether
chemotactic activity of induced sputum samples related to
the presence of LTB4, experiments were performed in the
presence and absence of an LTB4 receptor antagonist (10 mM
LY-223982; Eli Lilly, Basinstoke, UK) at 37°C. Chemotaxis
was performed as previously described (23) using a 48-well
microchemotaxis chamber (Neuro Probe; Costar, Cabin John,
MD). Neutrophils were loaded into the upper well and the
sputum supernatant diluted 1:4 was placed in the bottom
chamber. The two wells were separated by a polycarbonate
filter paper with a pore size of 3 mm. The chamber was
incubated at 37°C for 1 h. At the end of incubation, the filter
was fixed, stained, and mounted on a glass microscope slide
(observed at 3400). Migration was assessed by counting the
number of cells that had migrated beyond a certain depth
into the filter. Each experimental condition was performed in
duplicate, and three to four fields were assessed for cell
migration. The number of cells migrating spontaneously (i.e.,
negative controls) were subtracted from all measurements
before data analysis.
Statistical analysis. Results obtained from sputum sam-
ples were expressed as medians and 25 to 75 percentiles, and
statistical analysis was performed with Mann-Whitney’s U-
test. The Spearman rank correlation was calculated to assess
the correlation between data. Results obtained from isolated
cell preparation were expressed as means and SE of n repli-
cation, and statistical analysis was performed with Tukey-
Kramer’s honestly significant difference test.
RESULTS
Demographic characteristics of patients. FEV1 val-
ues of chronic bronchitis/COPD ranged from 23 to 98%
of that predicted (median and percentiles: 75 and 62 to
90%). In the chronic bronchitis group, 4 of 15 patients
had COPD because their FEV1 values were ,70%. All
patients had a normal total lung volume and diffusion
capacity, excluding superimposing emphysema.
Total and differential cell counts in sputum and
saliva. The percentage of squamous cells was not sig-
nificantly different in sputum samples obtained from
control subjects and chronic bronchitis patients (Table
1). The corrected median of total cell count resulted
higher in chronic bronchitis patients (1.9, 0.9–3.8 106
cells/ml) than in control subjects (1.2, 1–1.8 106 cells/
ml), although the difference was not statistically sig-
nificant. The viability of sputum cells was 75% (range:





Macrophages 81.8(80–89.4) 40.1(19.1–57.8) P , 0.001
Neutrophils 16.5(10–23) 57.3(26.4–78.6) P , 0.01
Lymphocytes 0(0–0.3) 0(0–0.5) ns
Eosinophils 0 0.5(0–2.2) P , 0.001
Epithelial cells 0(0–0.1) 2(0–7.2) ns
Differential cell counts of induced sputum samples obtained from
control and chronic bronchitis subjects. Data are expressed as medi-
ans (25–75 percentiles). Statistical analysis was performed using
Mann-Whitney’s U-test (ns, not significant).
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68–80%) in controls and 76% (range: 66–82%) in
chronic bronchitis. No significant correlation between
the cells’ viability and 15(S)-HETE levels was observed
in any group. The percentage of neutrophils was sig-
nificantly higher in chronic bronchitis patients than in
control subjects (P , 0.01). The percentage of eosino-
phils was also significantly higher in chronic bronchitis
patients than in control subjects (P , 0.001). No dif-
ferences were observed for lymphocytes and epithelial
cells (Table 1).
Soluble and cell-associated 15(S)-HETE in induced
sputum. 15(S)-HETE levels in the supernatants were
significantly higher in induced sputum obtained from
chronic bronchitis patients than in control subjects
(Fig. 1A; P , 0.03 Mann-Whitney’s U-test). To deter-
mine the possible role of 15(S)-HETE in cellular re-
cruitment, the concentration of 15(S)-HETE was corre-
lated with the number of macrophages and neutrophils
of induced sputum. In chronic bronchitis patients, the
levels of soluble 15(S)-HETE positively correlated with
the percentage of macrophages (P , 0.01) and in-
versely correlated with the percentage of neutrophils
(Fig. 2, A and B; P , 0.01). There was no significant
difference between the levels of soluble 15(S)-HETE in
induced sputum supernatants from chronic bronchitis
and COPD patients. 15(S)-HETE levels in saliva were
not detectable.
The levels of cell-associated 15(S)-HETE, measured
on base-catalyzed hydrolysis of cellular lipids, resulted
significantly higher in induced sputum of chronic bron-
chitis patients than in sputum of normal subjects (P ,
0.001, Mann-Whitney’s U-test; Fig. 1B). In chronic
bronchitis, the levels of cell-associated 15(S)-HETE
inversely correlated with the percentage of neutrophils
(Fig. 3A; P , 0.02). On the other hand, levels of cell-
associated 15(S)-HETE directly correlated with the
percentage of macrophages (Fig. 3B; P , 0.03). There
was no significant difference between the levels of
cell-associated 15(S)-HETE in chronic bronchitis and
COPD patients. Neither soluble nor cell-associated
15(S)-HETE showed statistically significant correla-
tion with the percentage of eosinophils. Neither soluble
nor cell-associated 15(S)-HETE showed correlation
with differential cell counts in control subjects. Cell-
associated 15(S)-HETE levels in cell pellets from saliva
were not detectable.
15-LO mRNA expression and immunohistochemis-
try. To evaluate whether cells recovered from induced
sputum were actively expressing 15-LO, we performed
PRINS for 15-LO mRNA on total cell populations re-
Fig. 1. 15(S)-hydroxyeicosatetraenoic acid
[15(S)-HETE] concentration in induced
sputum obtained from control and chronic
bronchitis patients. A: 15(S)-HETE con-
centration in supernatants. B: 15(S)-
HETE concentration in cellular lipids.
15(S)-HETE was analyzed by specific RIA
on reverse phase high-performance liquid
chromatography (RP-HPLC) separation.
15(S)-HETE was released from cellular
lipids by using base-catalyzed hydrolysis
as described in METHODS. Results are ex-
pressed as ng/106 cells. Statistical analy-
sis was performed with the use of Mann-
Whitney’s U-test.
Fig. 2. Correlation between the concentra-
tion (expressed as ng/106 cells) of 15(S)-HETE
in supernatants and the percentage of neu-
trophils (A) and macrophages (B) in induced
sputum samples obtained from chronic bron-
chitis patients. Statistical analysis was per-
formed with the use of the Spearman rank
test.
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covered from the two study groups. The percentage of
positive cells in induced sputum obtained from chronic
bronchitis (85%, range: 70–88%) (Fig. 4C) was signifi-
cantly higher than in control subjects (13%, range:
0–20%; Fig. 4C and Table 2; P , 0.01, Mann-Whitney’s
U-test), but no significant correlation was observed
between the 15(S)-HETE levels and the percentage of
cells expressing 15-LO mRNA. To identify the pheno-
type of cells expressing 15-LO mRNA, we performed
combined immunohistochemistry and in situ hybrid-
ization on cells recovered from induced sputum. Inter-
estingly, the transcripts for 15-LO were localized not
only in macrophages (Fig. 4D) but also in neutrophils
(Fig. 4E), as identified through labeling with a MAb
anti-CD68, specific for mononuclear phagocytes, and
with a MAb anti-elastase, specific for neutrophils.
Quantitative analysis of double-stained slides showed
that macrophages represented .83% of the cells ex-
pressing 15-LO mRNA (Table 2). 15-LO mRNA was
undetectable in squamous cells from induced sputum.
In agreement with previous results on the levels of
15-LO protein in blood polymorphonuclear leukocytes
from normal subjects (19), 15-LO mRNA was undetect-
able in neutrophils purified from peripheral blood of
normal subjects (data not shown), as well as from
chronic bronchitis patients (Fig. 4F).
Analysis of LTB4 in supernatants. To understand
whether the inverse relationship between 15(S)-HETE
levels and percentage of neutrophils involved modifi-
cation of the chemotactic factor LTB4, we measured
this mediator into sputum samples and found that
LTB4 inversely correlated with the observed values of
15(S)-HETE (Fig. 5; P , 0.001, Spearman rank test).
In vitro inhibitory effect of 15(S)-HETE on LTB4
production. Exogenous 15(S)-HETE inhibited LTB4
production elicited by the calcium ionophore A-23187
in isolated human neutrophils in a concentration-de-
pendent fashion (Fig. 6A). When a more physiological
stimulus was used (namely fMLP on GM-CSF prim-
ing), a nonsignificant increase in LTB4 production was
observed at concentrations of 15(S)-HETE lower than 1
mM, whereas at 3 and 10 mM, an inhibitory effect
similar to that obtained in A-23187-challenged cells
was observed (Fig. 6B).
Incubation of isolated neutrophils with 15(S)-HETE,
resulting in incorporation into cell phospholipids, fol-
lowed by washing of excess 15(S)-HETE, also resulted
in a significant inhibition of LTB4 production on GM-
CSF priming and fMLP challenge (232 6 6.5% vs.
control, n 5 4, P , 0.02).
Neutrophil chemotaxis assay. In chronic bronchitis
subjects, sputum samples with concentrations of 15(S)-
HETE ,8 ng/106 cells [low-15(S)-HETE producers]
caused a greater neutrophil chemotaxis than samples
with 15(S)-HETE concentrations .8 ng/106 cells [high-
15(S)-HETE producers] (Fig. 7A). In addition, preincu-
bation with the LTB4 receptor antagonist LY-223982
resulted in a greater inhibitory effect on neutrophil
chemotaxis induced by sputum from low-15(S)-HETE
producers than from high-15(S)-HETE producers (Fig.
7B).
DISCUSSION
The present results indicate that increased amounts
of 15(S)-HETE are present in induced sputum obtained
from chronic bronchitis patients compared with normal
subjects. 15(S)-HETE is also found associated with
cellular lipids, as an index of cellular incorporation of
this AA metabolite. The increased levels of 15(S)-
HETE observed are accompanied by a significant in-
crease in the percentage of cells expressing 15-LO
mRNA in chronic bronchitis patients. The concentra-
tion of either soluble or cell-associated 15(S)-HETE
shows a negative correlation with the percentage of
neutrophils in induced sputum in chronic bronchitis,
suggesting a potential modulatory role of this mediator
toward the migration of neutrophils into the airways.
Expression of 15-LO mRNA takes place in neutrophils
present in samples of induced sputum collected from
chronic bronchitis subjects but not in peripheral blood
neutrophils either from controls or from chronic bron-
chitis patients. Finally, we provide evidence that in-
creased 15(S)-HETE levels can modulate the produc-
tion of LTB4, resulting in a decreased neutrophil
chemotaxis activity in sputum samples.
Limited amounts of data are available concerning
values of 15(S)-HETE in human airways in vivo, and
Fig. 3. Correlation between the concentra-
tion of 15(S)-HETE, esterified in cellular
lipid, and the percentage of neutrophils (A)
and macrophages (B) in induced sputum sam-
ples obtained from chronic bronchitis pa-
tients. Statistical analysis was performed
with the use of the Spearman rank test.
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most of these data refer to bronchial asthma. Increased
levels of 15(S)-HETE were reported by Murray et al.
(22) in bronchoalveolar lavage fluids from atopic asth-
matic patients after specific challenge; on the other
hand, no differences were observed after specific chal-
lenge in aspirin-intolerant subjects (30). For the first
time, we provide evidence of highly significant differ-
ences in basal levels of this AA metabolite between
normal subjects and subjects characterized by inflam-
mation of the airways, such as chronic bronchitis.
15(S)-HETE can exert several biological actions that
may be relevant in the pathogenesis or the control of
airway inflammatory disorders. 15(S)-HETE has been
shown to be a potent mucosecretagogue in human
airways (20) and to possess chemotactic activity for
neutrophils directly contributing to the recruitment of
these cells in dog airways (10). Alternatively, it has
been reported that 15(S)-HETE inhibits 5-lipoxygen-
ase (5-LO) in neutrophils (24, 34), reducing the produc-
tion of inflammatory mediators such as LTB4, and
inhibits the changes in intracellular calcium concen-
trations induced by monocyte-derived neutrophil acti-
vating factor (31). The results of the present study
support the hypothesis that in chronic bronchitis,
15(S)-HETE exerts an inhibitory rather than a stimu-
latory effect on neutrophilic inflammation. We indeed
provide evidence that in chronic bronchitis, patient con-
centrations of free (soluble) 15(S)-HETE inversely cor-
relate with the percentage of infiltrating neutrophils, as
well as with the concentration of LTB4 in induced spu-
tum samples. In agreement with the latter observation,
exogenous 15(S)-HETE inhibits LTB4 production elicited
in isolated human neutrophils by challenge with either
A-23187 or fMLP after priming with GM-CSF.
The inverse correlation between concentrations of
LTB4 and concentrations of 15(S)-HETE was strength-
Fig. 4. A: induced sputum cells isolated
from chronic bronchitis subjects stained
for primed in situ labeling (PRINS), as
described in METHODS, using a random
sequence primer (negative control; orig-
inal magnification, 3160). B: expres-
sion of 15-lipoxygenase (15-LO) mRNA
on cytospin preparations of cells iso-
lated from induced sputum obtained from
a normal subjects (original magnifica-
tion, 3160). 15-LO mRNA was stained
using PRINS as described in METHODS. C:
expression of 15-LO mRNA on cytospin
preparations of cells isolated from in-
duced sputum obtained from a chronic
bronchitis subject (original magnifica-
tion, 3160). D and E: double staining of
induced sputum cells obtained from a
chronic bronchitis subject. Cells were
labeled with an anti-CD68 monoclonal
antibody (MAb; D) or with an anti-neu-
trophil elastase MAb (E) and then used
to perform PRINS of 15-LO mRNA, as
described in METHODS. The arrows indi-
cate cells that are double positive for
CD68 or for neutrophil elastase and
15-LO mRNA (original magnification,
3400). F: expression of 15-LO mRNA
on cytospin preparation of peripheral
blood human neutrophils that were ob-
tained from chronic bronchitis subjects
(original magnification, 3160).
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ened by the neutrophil chemotactic activity observed in
induced sputum samples from chronic bronchitis sub-
jects: chemotactic activity was significantly higher in
samples in which 15(S)-HETE concentration was low-
est (,8 ng/106 cells), compared with samples in which
15(S)-HETE concentration was higher than 8 ng/106
cells. Furthermore, the chemotactic activity of induced
sputum samples that showed low concentrations of
15(S)-HETE was significantly more sensitive to inhibi-
tion by an LTB4 receptor antagonist, indicating the
presence of higher concentrations of biologically active
LTB4.
In addition to the release, the incorporation of 15(S)-
HETE into membrane phospholipids impairs the re-
sponse of human polymorphonuclear neutrophil leuko-
cytes to inflammatory stimuli, such as the formylated
tripeptide fMLP (4), and inhibits the migration of neu-
trophils across cytokine-activated endothelium (32). In
agreement with these data, the concentrations of
15(S)-HETE associated with cellular lipids in induced
sputum samples from chronic bronchitis subjects in-
versely correlate with the percentage of infiltrating
neutrophils. Experiments in vitro confirmed that incor-
porated 15(S)-HETE significantly inhibits LTB4 pro-
duction elicited in isolated human neutrophils by chal-
lenge with fMLP after priming with GM-CSF.
Eosinophils are known to express 15-LO and may
represent a source of significant amounts of 15(S)-
HETE. Differential count of cells present in induced
sputum reveals that they only represent 1–2% of the
cells recovered, suggesting that they do not play a
major role in 15(S)-HETE production within the air-
ways of chronic bronchitis patients. This is supported
by the lack of a significant correlation between 15(S)-
HETE and the relative number of eosinophils, whereas
the strong positive correlation observed with macro-
phages proposes these cells as the most relevant with
respect to 15(S)-HETE production. The main role
played by macrophages may also explain why lower
levels of 15(S)-HETE in induced sputum were observed
in subjects with higher levels of neutrophils. In fact,
when the differential count of cells that express 15-LO
mRNA is taken into account, the ratio of macrophages
vs. neutrophils that express 15-LO mRNA is, on the
average, ;6:1. It is, therefore, likely that neutrophil-
derived 15(S)-HETE does not contribute significantly.
On the other hand, it is possible to speculate that
neutrophils that express 15-LO may become substan-
tially prevented from migrating into the airways, as
suggested by the reduced chemotaxis of neutrophils
that incorporate significant amounts of 15(S)-HETE
into their membrane phospholipids (4).
Fig. 5. Correlation between the levels of 15(S)-HETE and leukotri-
ene B4 (LTB4) measured in the supernatants of induced sputum from
chronic bronchitis subjects. 15(S)-HETE and LTB4 were measured
by specific RIA and enzyme immunoassay, respectively, on RP-HPLC
separation. Statistical analysis was performed with the use of the
Spearman rank test.
Fig. 6. Effect of exogenous 15(S)-HETE on the production of LTB4 by
isolated human neutrophils on challenge with the calcium ionophore
A-23187 (A) or formyl-methionine-leucine-phenylalanine after prim-
ing with granulocyte/macrophage colony-stimulating factor (B). Re-
sults are expressed as percent inhibition of the LTB4 production
observed in control samples.
Table 2. Differential cell counts of cells expressing
15-LO mRNA in induced-sputum samples
mRNA-Positive Cells, %
PControls Chronic bronchitis
Total cells 13 (0–20) 85 (70–88) , 0.001
Macrophages 3 (0–18) 70 (55.5–70) , 0.01
Neutrophils 0 (0–0) 14 (10–15) , 0.001
Lymphocytes 0 (0–1) 0 (0–1) ns
Eosinophils 0 (0–0) 0 (0–0) ns
Epithelial cells 0 (0–0.5) 0 (0–0) ns
Differential cell counts of induced sputum samples obtained from
control and chronic bronchitis subjects. 15-lipoxygenase (15-LO)
mRNA was detected by primed in situ labeling. Data are expressed
as medians (25–75 percentiles). Statistical analysis was performed
using Mann-Whitney’s U-test (ns, not significant).
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Expression of 15-LO mRNA and protein has been
reported in macrophages present in human atheroscle-
rotic lesions, where it has been implicated in foam cell
formation; 15-LO mRNA and 15-LO enzymatic activity
has also been reported in human alveolar macrophages
(17). With the use of in situ hybridization and immu-
nohistochemistry, we observed 15-LO mRNA expres-
sion in human alveolar macrophages and in infiltrating
neutrophils obtained from induced sputum of chronic
bronchitis patients. The presence of 15-LO in neutro-
phils obtained from peripheral blood has been a subject
of some controversy in the literature. Recently, when
using immunochemical analysis of supernatants from
highly purified neutrophils and eosinophils, one of us
(A. Sala) confirmed that neutrophils do not express
15-LO (19). Primed in situ labeling for 15-LO mRNA
coupled to immunohistochemistry confirms the ab-
sence of detectable transcripts for 15-LO in peripheral
blood neutrophils obtained either from normal or
chronic bronchitis subjects and indicates that expres-
sion of 15-LO is associated with induced migration of
neutrophils into the airways. Studies are under way in
our laboratories to identify the potential factor(s) re-
sponsible for such an effect. Expression of 15-LO by
inflammatory cells within the airways may be relevant
because 15-LO-derived products, in addition to 15(S)-
HETE, can contribute to modulate the inflammatory
response: lipoxin A4 and lipoxin B4, AA metabolites
arising from the sequential action of 5- and 15-LO,
inhibit LTB4- as well as fMLP-induced neutrophil che-
motaxis (15).
No correlation between the overall percentage of
cells that express 15-LO mRNA and 15(S)-HETE levels
was observed, possibly reflecting the fact that mRNA
expression, protein synthesis, and mediator formation/
release, represent different steps, certainly linked but
not strictly timewise correlated. Furthermore, we can-
not rule out a significant contribution to the observed
formation of 15(S)-HETE by airway epithelial cells or
submucosal eosinophils. The final information pro-
vided by the increased number of cells that express
15-LO mRNA in chronic bronchitis is that an active
process that results in increased formation of 15(S)-
HETE is taking place.
A wide variability in supernatant and cell-associated
15(S)-HETE was observed among chronic bronchitis
patients, but no significant differences, at least in
terms of functional parameters such as FEV1, could be
detected between high- and low-15(S)-HETE-produc-
ers. Nevertheless, it would be possible to speculate that
the decreased percentage of neutrophils present within
the airways of patients with high levels of 15(S)-HETE
may well be reflected in changes of the time course of
the chronic inflammatory response characteristic of
chronic bronchitis.
The ability of 15(S)-HETE to act as an immunoregu-
latory mediator for neutrophilic inflammation may
play a central role in the pathogenesis of chronic bron-
chitis. Neutrophilic inflammation appears to be an
important inflammatory component of the disease.
Bronchoalveolar lavage studies carried out in patients
with chronic bronchitis showed an increased number of
neutrophils, compared with normal subjects, as well as
increased levels of myeloperoxidase, a neutrophilic se-
cretory protein (13, 21). The factors contributing to the
recruitment of neutrophils in the bronchoalveolar la-
vage fluid is still a matter of discussion, but it has been
demonstrated that cigarette smoking increases their
numbers in the alveolar septum (18). Many factors
control how neutrophils pass through the lungs, in-
cluding the increased release of the neutrophil-chemo-
tactic cytokines interleukin-8 and tumor necrosis fac-
tor-a, the unique and complex structure of the
pulmonary capillary bed, the local hemodynamic fac-
tors, the neutrophil deformability, and neutrophil-en-
dothelial interactions. As a consequence of these com-
plex mechanisms, neutrophils from patients with
chronic bronchitis have an increased chemotaxis,
which suggests that they can be recruited more easily
in the lungs (5) and represent a potential cause for
increased proteolytic activity in the airways. Interest-
ingly, although the mechanisms modulating neutro-
phil migration and activation in the lung have been
extensively studied, little information is available with
respect to mechanisms involved in the modulation of
neutrophilic infiltration. The results of the present
study may add important evidence, because they
strongly suggest that increased 15(S)-HETE levels
Fig. 7. A: chemotaxis activity of superna-
tant fluids that were obtained from in-
duced sputum of chronic bronchitis sub-
jects showing 15(S)-HETE concentrations
,8 ng/106 cells [low-15(S)-HETE produc-
ers] and .8 ng/106 cells [high-15(S)-HETE
producers]. Results are expressed as the
number of migrated neutrophils per high
power field. B: effect of LY-223982 on neu-
trophil chemotaxis activity of induced spu-
tum samples that were obtained from low-
or high-15(S)-HETE producers. Results
are expressed as percentage inhibition vs.
control samples. Statistical analysis was
performed with the use of Mann-Whit-
ney’s U-test. *P , 0.05.
C1256 15-LO IN INDUCED SPUTUM
Downloaded from journals.physiology.org/journal/ajpcell at Biblioteca Polo Didattico (159.149.207.220) on May 5, 2021.
may serve as a negative regulatory mechanism of neu-
trophil recruitment and activation in chronic bronchi-
tis, modulating the synthesis of the chemotactic factor
LTB4.
In conclusion, analysis of 15(S)-HETE in superna-
tants [soluble 15(S)-HETE] from induced sputum sam-
ples provides evidence for significantly increased levels
of this AA metabolite in inflamed airways of chronic
bronchitis patients. Increased concentrations of 15(S)-
HETE are also present in cellular lipids [cell-associ-
ated 15(S)-HETE] and may contribute to the potential
effects of this mediator. A significant negative correla-
tion between the concentrations of either soluble or
cell-associated 15(S)-HETE and the percentage of neu-
trophils in chronic bronchitis patients suggests a role
of 15(S)-HETE in modulating neutrophilic infiltration.
Expression of 15(S)-HETE mRNA is observed in neu-
trophils present in induced sputum but not in neutro-
phils obtained from peripheral blood, suggesting that
expression of 15-LO may take place on migration of
neutrophils within the airways of chronic bronchitis
patients. 15-LO expression and 15(S)-HETE produc-
tion, as well as incorporation of this AA metabolite into
cellular lipids, may represent important regulatory
mechanisms that operate in pulmonary inflammation,
inhibiting the production of 5-LO metabolites such as
LTB4, and, consequently, the infiltration of neutrophils
within the airways of chronic bronchitis subjects.
We thank Prof. G. Folco for helpful discussion.
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